Highlights ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Real-time Estimate Cboe BZX Other stock markets 11:29:30 2024-05-13 am EDT			5-day change	1st Jan Change
9.115 ^USD	+1.39%		-2.03%	-0.22%

May. 06	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	Apr. 15	MT
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	Apr. 15	CI
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	Apr. 08	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944	Jan. 08	CI
ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology Annual Meeting	Dec. 11	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations	23-10-21	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Pfizer Discloses 12% Stake in ORIC Pharmaceuticals	22-12-30	MT
Investor Caution Ahead of GDP Data, Jobless Claims Subdues Exchange-Traded Funds, Equity Futures Premarket	22-12-22	MT
Oric Pharmaceuticals Shares Soar on Pfizer's $25 Million Investment	22-12-22	DJ
ORIC Pharmaceuticals Enters Multiple Myeloma Collaboration With Pfizer; Set to Get $25 Million Equity Investment	22-12-22	MT
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer	22-12-21	CI
ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting	22-12-13	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Highlights

Filters